FINEGUST

Completed

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

Lead sponsor

Bayer

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

50,000

Study population

Cardiovascular disease, Chronic kidney disease, Heart failure, Obesity / overweight, Type 2 diabetes

Eligibility highlights

Primary endpoints

•Descriptive summary of baseline patient characteristics•Descriptive summary of patient comorbidities•Descriptive summary of patient comedications

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05526157

Org study ID21956

Timeline

Milestones

Study first posted2022-09-02actual

Study start2022-10-01actual

Primary completion2024-09-05actual

Study completion2024-09-05actual

Last update posted2024-10-15actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Cardiovascular diseaseChronic kidney diseaseHeart failureObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

The study will be conducted using data from data sources in 5 countries: Denmark (the Danish National Health Registers), Japan (the Japan Chronic Kidney Disease Database), the Netherlands (PHARMO), Spain (the Valencia Health System Integrated Database), and the US (Optum). For each database, the source population will include patients who fulfil an electronic algorithm for CKD and T2D.

Inclusion criteria

•Active registration or continuous enrolment for at least 12 months in 1 of the selected data sources before the index date

•No recorded prescription or dispensing of any medication in the class during the 12 months before the index date

•Age 18 years or older as of the index date

•Diagnosis of T2D on or before the index date

•Diagnosis of CKD on or before the index date

Exclusion criteria

•Type 1 diabetes identified by appropriate algorithms in each participating data source

•Kidney cancer on or before the index date

•Kidney failure

-- Maintenance dialysis on or before the index date

•Kidney transplantation on or before the index date

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

Descriptive summary of baseline patient characteristics

Time frame:Baseline study periods I and II

descriptive

Primary/protocol endpoint/low confidence

Descriptive summary of patient comorbidities

Time frame:Baseline study periods I and II

descriptive

Primary/protocol endpoint/low confidence

Descriptive summary of patient comedications

Time frame:Baseline study periods I and II

descriptive

Secondary/protocol endpoint/low confidence

Descriptive summary of changes over time in treatments in the new-user cohorts

Time frame:From Day 1 until Censor Day (at the earliest of death, disenrolment, exclusion criteria during follow-up, or end of the study period) [up to 114 months for study period I and up to 39 months for study period II].

descriptive

Secondary/protocol endpoint/low confidence

Descriptive summary of temporal changes in the baseline characteristics of medication-specific cohorts

Time frame:Baseline up to 114 months for study period I and up to 39 months for study period II

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.